Treatment of ocular inflammatory disorders with daclizumab.

PURPOSE: To evaluate the efficacy and safety of daclizumab therapy for patients with various ophthalmologic inflammatory disorders (all having previously failed standard treatment methods).

DESIGN

Retrospective, nonrandomized case series.

PARTICIPANTS

Fourteen patients.

METHODS

Fourteen patients were treated with daclizumab after previously failing standard treatment methods.

MAIN OUTCOME MEASURES: Inflammation and visual acuity.

RESULTS

Twelve of 27 (44%) eyes and 5 of 14 (36%) patients had improvement in visual acuity; 9 of 27 (33%) eyes and 5 of 14 (36%) patients had no change in visual acuity; and 6 of 27 (22%) eyes and 4 of 14 (27%) patients had continued visual loss. Based on degree of inflammation, 16 of 27 eyes (59%) had improvement, 3 of 27 (11%) eyes had no change, and 8 of 27 (30%) eyes worsened.

CONCLUSIONS

Daclizumab is safe and, at least in some patients, appears to be an effective medication in the treatment of ocular inflammatory disorders.